Interleukin inhibitors represent a promising therapeutic approach for the treatment of refractory gout.By blocking these interleukins,such as IL-1β and IL-6,these biologic drugs can effectively reduce inflammation and alleviate symptoms in patients who do not respond adequately to conventional therapies like nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.

The global Interleukin Inhibitors for the Treatment of Refractory Gout market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Interleukin Inhibitors for the Treatment of Refractory Gout is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Interleukin Inhibitors for the Treatment of Refractory Gout is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout include Novartis, Sobi, Roche, Biogen, Fresenius Kabi, Hetero, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Hangzhou Bozhirui Biopharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Interleukin Inhibitors for the Treatment of Refractory Gout, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interleukin Inhibitors for the Treatment of Refractory Gout.

The Interleukin Inhibitors for the Treatment of Refractory Gout market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Interleukin Inhibitors for the Treatment of Refractory Gout market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Interleukin Inhibitors for the Treatment of Refractory Gout manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Interleukin Inhibitors for the Treatment of Refractory Gout Market Report

Report Metric	Details
Report Name	Interleukin Inhibitors for the Treatment of Refractory Gout Market
Segment by Type	Canakinumab Anakinra Tocilizumab
Segment by Application	Hospital and Clinic Retail Pharmacies Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novartis, Sobi, Roche, Biogen, Fresenius Kabi, Hetero, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Hangzhou Bozhirui Biopharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Interleukin Inhibitors for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Interleukin Inhibitors for the Treatment of Refractory Gout in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Interleukin Inhibitors for the Treatment of Refractory Gout Market report?

Ans: The main players in the Interleukin Inhibitors for the Treatment of Refractory Gout Market are Novartis, Sobi, Roche, Biogen, Fresenius Kabi, Hetero, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Hangzhou Bozhirui Biopharmaceutical

What are the Application segmentation covered in the Interleukin Inhibitors for the Treatment of Refractory Gout Market report?

Ans: The Applications covered in the Interleukin Inhibitors for the Treatment of Refractory Gout Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Interleukin Inhibitors for the Treatment of Refractory Gout Market report?

Ans: The Types covered in the Interleukin Inhibitors for the Treatment of Refractory Gout Market report are Canakinumab, Anakinra, Tocilizumab

1 Interleukin Inhibitors for the Treatment of Refractory Gout Market Overview

1.1 Product Definition

1.2 Interleukin Inhibitors for the Treatment of Refractory Gout by Type

1.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030)

1.2.2 Canakinumab

1.2.3 Anakinra

1.2.4 Tocilizumab

1.3 Interleukin Inhibitors for the Treatment of Refractory Gout by Application

1.3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value by Application (2024-2030)

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size Estimates and Forecasts

1.4.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue 2019-2030

1.4.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales 2019-2030

1.4.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Interleukin Inhibitors for the Treatment of Refractory Gout Market Competition by Manufacturers

2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2019-2024)

2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Interleukin Inhibitors for the Treatment of Refractory Gout, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Product Type & Application

2.7 Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Date of Enter into This Industry

2.8 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Competitive Situation and Trends

2.8.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Interleukin Inhibitors for the Treatment of Refractory Gout Players Market Share by Revenue

2.8.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Scenario by Region

3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region: 2019-2030

3.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region: 2019-2024

3.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region: 2025-2030

3.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region: 2019-2030

3.3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region: 2019-2024

3.3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region: 2025-2030

3.4 North America Interleukin Inhibitors for the Treatment of Refractory Gout Market Facts & Figures by Country

3.4.1 North America Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.4.3 North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Market Facts & Figures by Country

3.5.1 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.5.3 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Market Facts & Figures by Region

3.6.1 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2019-2030)

3.6.3 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Market Facts & Figures by Country

3.7.1 Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.7.3 Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Market Facts & Figures by Country

3.8.1 Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2030)

3.8.3 Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2019-2030)

4.1.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2019-2024)

4.1.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2025-2030)

4.1.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2019-2030)

4.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2019-2030)

4.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2019-2024)

4.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2025-2030)

4.2.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2030)

4.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Price by Type (2019-2030)

5 Segment by Application

5.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2019-2030)

5.1.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2019-2024)

5.1.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2025-2030)

5.1.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2019-2030)

5.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2019-2030)

5.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2019-2024)

5.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2025-2030)

5.2.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2019-2030)

5.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novartis

6.1.1 Novartis Company Information

6.1.2 Novartis Description and Business Overview

6.1.3 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.1.5 Novartis Recent Developments/Updates

6.2 Sobi

6.2.1 Sobi Company Information

6.2.2 Sobi Description and Business Overview

6.2.3 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.2.5 Sobi Recent Developments/Updates

6.3 Roche

6.3.1 Roche Company Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 Biogen

6.4.1 Biogen Company Information

6.4.2 Biogen Description and Business Overview

6.4.3 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.4.5 Biogen Recent Developments/Updates

6.5 Fresenius Kabi

6.5.1 Fresenius Kabi Company Information

6.5.2 Fresenius Kabi Description and Business Overview

6.5.3 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.5.5 Fresenius Kabi Recent Developments/Updates

6.6 Hetero

6.6.1 Hetero Company Information

6.6.2 Hetero Description and Business Overview

6.6.3 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.6.5 Hetero Recent Developments/Updates

6.7 Bio-Thera Solutions

6.7.1 Bio-Thera Solutions Company Information

6.7.2 Bio-Thera Solutions Description and Business Overview

6.7.3 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.7.5 Bio-Thera Solutions Recent Developments/Updates

6.8 Zhuhai Livzon Biotechnology

6.8.1 Zhuhai Livzon Biotechnology Company Information

6.8.2 Zhuhai Livzon Biotechnology Description and Business Overview

6.8.3 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.8.5 Zhuhai Livzon Biotechnology Recent Developments/Updates

6.9 Hangzhou Bozhirui Biopharmaceutical

6.9.1 Hangzhou Bozhirui Biopharmaceutical Company Information

6.9.2 Hangzhou Bozhirui Biopharmaceutical Description and Business Overview

6.9.3 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio

6.9.5 Hangzhou Bozhirui Biopharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Chain Analysis

7.2 Interleukin Inhibitors for the Treatment of Refractory Gout Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Interleukin Inhibitors for the Treatment of Refractory Gout Production Mode & Process

7.4 Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Marketing

7.4.1 Interleukin Inhibitors for the Treatment of Refractory Gout Sales Channels

7.4.2 Interleukin Inhibitors for the Treatment of Refractory Gout Distributors

7.5 Interleukin Inhibitors for the Treatment of Refractory Gout Customers

8 Interleukin Inhibitors for the Treatment of Refractory Gout Market Dynamics

8.1 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Trends

8.2 Interleukin Inhibitors for the Treatment of Refractory Gout Market Drivers

8.3 Interleukin Inhibitors for the Treatment of Refractory Gout Market Challenges

8.4 Interleukin Inhibitors for the Treatment of Refractory Gout Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Zhuhai Livzon Biotechnology

Hangzhou Bozhirui Biopharmaceutical

List of Tables

Table 1. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Competitive Situation by Manufacturers in 2023

Table 4. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Interleukin Inhibitors for the Treatment of Refractory Gout Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Interleukin Inhibitors for the Treatment of Refractory Gout, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Product Type & Application

Table 12. Global Key Manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Interleukin Inhibitors for the Treatment of Refractory Gout by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Interleukin Inhibitors for the Treatment of Refractory Gout as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2019-2024) & (K Units)

Table 18. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Region (2019-2024)

Table 19. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2025-2030) & (K Units)

Table 20. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Region (2025-2030)

Table 21. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2019-2024)

Table 23. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2025-2030)

Table 25. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 27. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 28. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 32. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 33. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units) by Type (2019-2024)

Table 51. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units) by Type (2025-2030)

Table 52. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2019-2024)

Table 53. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2025-2030)

Table 54. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2024)

Table 57. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2025-2030)

Table 58. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Type (2019-2024)

Table 59. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Type (2025-2030)

Table 60. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units) by Application (2019-2024)

Table 61. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units) by Application (2025-2030)

Table 62. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2019-2024)

Table 63. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2025-2030)

Table 64. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2019-2024)

Table 67. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2025-2030)

Table 68. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Application (2019-2024)

Table 69. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Application (2025-2030)

Table 70. Novartis Company Information

Table 71. Novartis Description and Business Overview

Table 72. Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 74. Novartis Recent Developments/Updates

Table 75. Sobi Company Information

Table 76. Sobi Description and Business Overview

Table 77. Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 79. Sobi Recent Developments/Updates

Table 80. Roche Company Information

Table 81. Roche Description and Business Overview

Table 82. Roche Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Roche Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 84. Roche Recent Developments/Updates

Table 85. Biogen Company Information

Table 86. Biogen Description and Business Overview

Table 87. Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 89. Biogen Recent Developments/Updates

Table 90. Fresenius Kabi Company Information

Table 91. Fresenius Kabi Description and Business Overview

Table 92. Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 94. Fresenius Kabi Recent Developments/Updates

Table 95. Hetero Company Information

Table 96. Hetero Description and Business Overview

Table 97. Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 99. Hetero Recent Developments/Updates

Table 100. Bio-Thera Solutions Company Information

Table 101. Bio-Thera Solutions Description and Business Overview

Table 102. Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 104. Bio-Thera Solutions Recent Developments/Updates

Table 105. Zhuhai Livzon Biotechnology Company Information

Table 106. Zhuhai Livzon Biotechnology Description and Business Overview

Table 107. Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 109. Zhuhai Livzon Biotechnology Recent Developments/Updates

Table 110. Hangzhou Bozhirui Biopharmaceutical Company Information

Table 111. Hangzhou Bozhirui Biopharmaceutical Description and Business Overview

Table 112. Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Product

Table 114. Hangzhou Bozhirui Biopharmaceutical Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Interleukin Inhibitors for the Treatment of Refractory Gout Distributors List

Table 118. Interleukin Inhibitors for the Treatment of Refractory Gout Customers List

Table 119. Interleukin Inhibitors for the Treatment of Refractory Gout Market Trends

Table 120. Interleukin Inhibitors for the Treatment of Refractory Gout Market Drivers

Table 121. Interleukin Inhibitors for the Treatment of Refractory Gout Market Challenges

Table 122. Interleukin Inhibitors for the Treatment of Refractory Gout Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Interleukin Inhibitors for the Treatment of Refractory Gout

Figure 2. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Share by Type: 2023 & 2030

Figure 4. Canakinumab Product Picture

Figure 5. Anakinra Product Picture

Figure 6. Tocilizumab Product Picture

Figure 7. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Value by Application (2024-2030) & (US$ Million)

Figure 8. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Share by Application: 2023 & 2030

Figure 9. Hospital and Clinic

Figure 10. Retail Pharmacies

Figure 11. Other

Figure 12. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size (2019-2030) & (US$ Million)

Figure 14. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (2019-2030) & (K Units)

Figure 15. Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price (US$/Unit) & (2019-2030)

Figure 16. Interleukin Inhibitors for the Treatment of Refractory Gout Report Years Considered

Figure 17. Interleukin Inhibitors for the Treatment of Refractory Gout Sales Share by Manufacturers in 2023

Figure 18. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Manufacturers in 2023

Figure 19. Global 5 and 10 Largest Interleukin Inhibitors for the Treatment of Refractory Gout Players: Market Share by Revenue in Interleukin Inhibitors for the Treatment of Refractory Gout in 2023

Figure 20. Interleukin Inhibitors for the Treatment of Refractory Gout Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 21. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 23. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 24. United States Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 27. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 28. Germany Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2019-2030)

Figure 35. China Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 43. Mexico Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Colombia Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2019-2030)

Figure 48. Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Interleukin Inhibitors for the Treatment of Refractory Gout by Type (2019-2030)

Figure 53. Global Revenue Market Share of Interleukin Inhibitors for the Treatment of Refractory Gout by Type (2019-2030)

Figure 54. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Interleukin Inhibitors for the Treatment of Refractory Gout by Application (2019-2030)

Figure 56. Global Revenue Market Share of Interleukin Inhibitors for the Treatment of Refractory Gout by Application (2019-2030)

Figure 57. Global Interleukin Inhibitors for the Treatment of Refractory Gout Price (US$/Unit) by Application (2019-2030)

Figure 58. Interleukin Inhibitors for the Treatment of Refractory Gout Value Chain

Figure 59. Interleukin Inhibitors for the Treatment of Refractory Gout Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions